Breaking News

Tweet TWEET

Biostar Pharmaceuticals, Inc. Announces the Designation of its PRC Operating Subsidiary as the Shaanxi Province Liver Disease

 Biostar Pharmaceuticals, Inc. Announces the Designation of its PRC Operating
    Subsidiary as the Shaanxi Province Liver Disease Health Education Base

PR Newswire

XIANYANG, China, Jan. 15, 2014

XIANYANG, China, Jan. 15, 2014 /PRNewswire/ -- Biostar Pharmaceuticals, Inc.
(NASDAQ: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and
marketer of pharmaceutical and health supplement products in China for a
variety of diseases and conditions, today announced that its PRC operating
subsidiary was designated as the Shaanxi Province Liver Disease Health
Education Base.

On January 9, 2014, Mr. Ronghua Wang, the CEO of the Company, attended the
opening ceremony of Shaanxi Pharmaceutical and Health Products Cooperation
Association held at Xi'an International Health Industrial Park headquarters,
at which event Shaanxi Aoxing Pharmaceutical Co., Ltd., the Company's PRC
operating subsidiary, was awarded several honors of Shaanxi Pharmaceutical and
Health Products Cooperation Association Director Unit and was designated as
the Shaanxi Province Liver Disease Health Education Base.

Shaanxi Aoxing Pharmaceutical Co., Ltd. has been engaged in the research and
development of liver disease products for more than a decade. Its product,
Aoxing No.1 Oleanolic Acid Capsule, enjoys solid reputation in Shaanxi and
northwest region of China and its sales continue to consistently increase. At
the end of 2013, Aoxing No.1 Oleanolic Acid Injection completed testing of
production technology and product stability.

In connection with the foregoing award and designation, Mr. Wang commented
that "the Company's designation as the Liver Disease Health Education Base
will provide a new platform for promotion, research and development of our
Hepatitis B product. We will seize this opportunity to expand the reach of our
product line and to accelerate the new product development cycle. The
incidence of Hepatitis B in China remains high. We strive to produce high
quality treatment medication for the affected patients and intend to continue
on this important, public health mission", he concluded.

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and
controlled affiliate in China, develops, manufactures and markets
pharmaceutical and health supplement products for a variety of diseases and
conditions.The Company's most popular product is its Xin Aoxing Oleanolic
Acid Capsule, an over-the-counter ("OTC") medicine for chronic Hepatitis B, a
disease affecting approximately 10% of the Chinese population. For more
information please visit: http://www.biostarpharmaceuticals.com.

Safe Harbor Relating to the Forward-Looking Statements

Certain statements in this release concerning our future growth prospects are
forward-looking statements, within the meaning of Section 27A of the U.S.
Securities Act of 1933, as amended, and Section 21E of the U.S. Securities
Exchange Act of 1934, as amended, which involve a number of risks and
uncertainties that could cause actual results to differ materially from those
in such forward-looking statements. The company uses words and phrases such as
"guidance," "forecasted," "projects," "is expected," "remain confident,"
"will" and similar expressions to identify forward-looking statements in this
press release, including forward-looking statements. Undue reliance should not
be placed on forward-looking information. Forward-looking information is based
on current expectations, estimates and projections that involve a number of
risks, which could cause actual results to vary and in some instances to
differ materially from those anticipated by Biostar and described in the
forward-looking information contained in this news release. The risks and
uncertainties relating to these statements include, but are not limited to,
risks and uncertainties regarding the Company's ability to achieve the
projected sales in the recently opened sales offices, to complete the
contemplated clinical trials and capitalize on such opportunities, the
Company's ability to recover its sales and revenue for the gel capsule segment
of its business, the state of consumer confidence and market demand or the
Company's products, success of our investments, risks and uncertainties
regarding fluctuations in earnings, our ability to sustain our previous levels
of profitability including on account of our ability to manage growth, intense
competition, wage increases in China, our ability to attract and retain highly
skilled professionals, time and cost overruns on fixed-price, fixed-time frame
contracts, client concentration, our ability to successfully complete and
integrate potential acquisitions, withdrawal of governmental fiscal
incentives, political instability and regional conflicts and legal
restrictions on raising capital or acquiring companies outside China.
Additional risks that could affect our future operating results are more fully
described in our United States Securities and Exchange Commission filings
including our most recent Annual Report on Form 10-K for the year ended
December 31, 2012, and other subsequent filings. These filings are available
atwww.sec.gov. We may, from time to time, make additional written and oral
forward-looking statements, including statements contained in our filings with
the Securities and Exchange Commission and our reports to shareholders. We do
not undertake to update any forward-looking statements that may be made from
time to time by or on our behalf.

SOURCE Biostar Pharmaceuticals, Inc.

Website: http://www.biostarpharmaceuticals.com/
Contact: Biostar Pharmaceuticals, Inc., Ally Gong, +86-29-3368-6638,
office@aoxing-group.com / Chineseinvestors.com Inc, Alice, +86-4001200987,
info@chinesefn.com